Johnson & Johnson09.04.19
Johnson & Johnson Medical Devices Companies* announced that DePuy Synthes Products Inc. has signed a definitive agreement with JointPoint Inc. to acquire its surgeon-friendly navigation software designed to improve surgical outcomes in hip replacement. The transaction, expected to close this year, is subject to customary closing conditions. Financial terms of the acquisition are not being disclosed.
JointPoint Navigation Software provides surgeons performing hip replacements with a precise analysis of implant selection and positioning through easy-to-use non-invasive computer navigation, pre-surgical digital templating and case planning. This in turn may lead to more reproducible clinical outcomes. An important feature of the JointPoint software is OneTrial, which is used to optimize implant combinations based on pre-surgical goals with just two images, and reduce OR time by limiting retrialing.
“JointPoint ties into our strategy to transform hip replacement and is specifically designed for use with the Anterior Approach, a tissue-sparing surgical technique which surgeons are increasingly utilizing and where we have long had an industry-leading presence,” said Aaron Villaruz, vice president and global platform leader, Hips, DePuy Synthes.
Since July 2017, DePuy Synthes has had an exclusive co-marketing agreement to market the JointPoint platform in the United States. Upon close of the transaction, the JointPoint platform will become a DePuy Synthes-owned component of an Anterior Approach solution called the ANTERIOR ADVANTAGE which brings together DePuy Synthes implants and instrumentation, exclusive technologies to optimize the surgical experience for the patient, and a professional education program designed to decrease the learning curve and increase surgical reproducibility.
Among the components of the ANTERIOR ADVANTAGE is the KINCISE Surgical Automated System, which automates and improves the precision of key steps during hip replacement surgery and is compatible with the JointPoint platform. Another component of ANTERIOR ADVANTAGE is the ACTIS Total Hip System. Both the KINCISE System and ACTIS System can also be used in traditional posterior approaches to hip replacement.
DePuy Synthes plans to continue to develop and broaden the JointPoint platform for additional orthopedic surgery procedures.
Johnson & Johnson Medical Devices Companies builds on more than a century of expertise to tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopedics, vision, and interventional solutions, the company helps save lives and paves the way to a healthier future.
DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides a comprehensive orthopedics portfolio. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide.
*The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.
JointPoint Navigation Software provides surgeons performing hip replacements with a precise analysis of implant selection and positioning through easy-to-use non-invasive computer navigation, pre-surgical digital templating and case planning. This in turn may lead to more reproducible clinical outcomes. An important feature of the JointPoint software is OneTrial, which is used to optimize implant combinations based on pre-surgical goals with just two images, and reduce OR time by limiting retrialing.
“JointPoint ties into our strategy to transform hip replacement and is specifically designed for use with the Anterior Approach, a tissue-sparing surgical technique which surgeons are increasingly utilizing and where we have long had an industry-leading presence,” said Aaron Villaruz, vice president and global platform leader, Hips, DePuy Synthes.
Since July 2017, DePuy Synthes has had an exclusive co-marketing agreement to market the JointPoint platform in the United States. Upon close of the transaction, the JointPoint platform will become a DePuy Synthes-owned component of an Anterior Approach solution called the ANTERIOR ADVANTAGE which brings together DePuy Synthes implants and instrumentation, exclusive technologies to optimize the surgical experience for the patient, and a professional education program designed to decrease the learning curve and increase surgical reproducibility.
Among the components of the ANTERIOR ADVANTAGE is the KINCISE Surgical Automated System, which automates and improves the precision of key steps during hip replacement surgery and is compatible with the JointPoint platform. Another component of ANTERIOR ADVANTAGE is the ACTIS Total Hip System. Both the KINCISE System and ACTIS System can also be used in traditional posterior approaches to hip replacement.
DePuy Synthes plans to continue to develop and broaden the JointPoint platform for additional orthopedic surgery procedures.
Johnson & Johnson Medical Devices Companies builds on more than a century of expertise to tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopedics, vision, and interventional solutions, the company helps save lives and paves the way to a healthier future.
DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides a comprehensive orthopedics portfolio. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide.
*The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.